For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>Naftidrofuryl is a drug used in the management of peripheral and cerebral vascular disorders as a vasodilator, enhance cellular oxidative capacity, and may also be a 5-HT2 receptor antagonist.<br>Target: 5-HT2 receptor<br>Naftidrofuryl may be effective for relieving the pain of muscle cramps.[1]<br>Naftidrofuryl oxalate is the only vasoactive drug for peripheral arterial disease (PAD) which is likely to be cost-effective.[2]<br>Naftidrofuryl oxalate is ranked first for both maximum walking distance (MWD) and pain-free walking distance (PFWD) (probability of 0·947 and 0·987, respectively, of being the best treatment) followed by cilostazol and pentoxifylline.<br>Naftidrofuryl oxalate is effective treatments for claudication, Naftidrofuryl oxalate is likely to be the most effective, with minimal serious adverse events.[3]</p>
| Catalog Number | I000039 |
| CAS Number | 3200-06-4 |
| Molecular Formula | C26H35NO7 |
| Purity | ≥95% |
| Target | 5-HT2 receptor |
| Solubility | 10 mM in H2O |
| Storage | -20°C |
| Reference | <p style=/line-height:25px/> <br>[2]. Meng Y, et al. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Angiology. 2014 Mar;65(3):190-197. <br>[3]. Stevens JW, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012 Dec;99(12):1630-1638. </p> |
